Skip to main content
Premium Trial:

Request an Annual Quote

Caris Life Sciences, Essa Pharma Ink Liquid Biopsy Partnership for Prostate Cancer Trial

NEW YORK – Caris Life Sciences and Essa Pharma said on Thursday that they have teamed up to genetically characterize patients enrolled in a Phase I trial of Essa's investigational prostate cancer drug, EPI-7386.

For its part of the collaboration, Caris will use its blood-based whole transcriptome sequencing and whole exome sequencing tests to assess all 22,000 genes in each trial participants' DNA and RNA. The Phase I trial is assessing the safety and preliminary efficacy of EPI-7386, an N-terminal domain androgen receptor, in 64 patients with metastatic castration-resistant prostate cancer whose disease has progressed after standard-of-care treatment.

Essa plans to use longitudinal data from repeat testing using Caris' liquid biopsies to characterize patients' tumor biological profiles, which will "facilitate a more efficient development of EPI-7386 in patient tumor biological subpopulations," Essa CEO David Parkinson said in a statement. 

Although Essa is using Caris liquid biopsies to home in on the population of mCRPC most likely to respond to the agent according to genetic characterization, the primary endpoint of the trial is the percent of patients whose blood concentration of prostate-specific antigen declines by at least 50 percent at any point during treatment with EPI-7386.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.